Celgene Near Acquisition of Impact Biomedicines

Celgene Corp. is nearing an accord to acquire closely held Impact Biomedicines Inc. to expand its presence in oncology, according to people familiar with the matter.

An agreement could be announced as early as Monday, said the people, who asked not to be identified because talks are private. The deal could still be delayed or fall apart, they said. The Wall Street Journal said Celgene could pay as much as $7 billion over time for the asset.